Tag: Cancer: Leukemia
Allo-HCT With Unrelated Donor Tied to Better Outcomes in AML
In active AML, outcomes superior for allo-HCT with unrelated donor than for cord blood transplantation
ASCO: Combo Regimen Effective in CLL With Coexisting Conditions
Progression-free survival longer with venetoclax-obinutuzumab versus chlorambucil-obinutuzumab
Ibrutinib, Venetoclax Active in High-Risk, Seniors With CLL
Findings seen in phase 2 study of combo regimen for first-line treatment of chronic lymphocytic leukemia
Octogenarians With Acute Myeloid Leukemia Have Poor Survival
Overall survival 1.5 months; survival improved for those receiving chemotherapy
FDA Approves Venetoclax for Chronic Lymphocytic Leukemia
In randomized trial, drug demonstrated statistically significant improvement in progression-free survival
FDA Approves Venetoclax for Chronic, Small Lymphocytic Leukemia
In randomized trial, drug demonstrated statistically significant improvement in progression-free survival
iADL Dependency May Up Mortality in Hematologic Cancers
Instrumental activities of daily living dependency, mortality linked in seniors with hematologic cancer
Reasons for TKI Discontinuation ID’d in Chronic Myeloid Leukemia
Treatment-free remission maintained in 14 of 21 patients who discontinued tyrosine kinase inhibitors
Presence of Leukemia Cutis Tied to Worse Survival in AML
Hazard ratios for leukemia-specific death, all-cause death higher for patients with AML and LC
Population Mortality Affects Long-Term Follow-Up of AlloHCT
Substantial part of total nonrelapse mortality for older patients due to population mortality
